Streptococcus pneumoniae<\/em> no inclosos en les vacunes actuals.<\/p>\nL’estudi, dut a terme entre 2019 i 2021, forma part d’una investigaci\u00f3 col\u00b7laborativa que s’emmarca en la L\u00ednia de Pneum\u00f2nia de CIBERs i que ha comptat amb el finan\u00e7ament de l’Institut de salut Carlos III (ISCIII). Des de fa m\u00e9s de 12 anys, participen en aquest projecte hospitals de diferents regions d’Espanya (Hospital General Universitari Gregorio Mara\u00f1\u00f3n [Madrid]; Hospital Universitari de Donostia [Pa\u00eds Basc]; l’Hospital Vall d’Hebron, Consorci Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, Hospital Universitari Germans Trias i Pujol i Hospital Universitari de Bellvitge [Catalunya]) i el Laboratori de Refer\u00e8ncia de Pneumococs de l’ISCIII. Aquest estudi ha recollit m\u00e9s de 650 casos d’MPI, sent la pneum\u00f2nia el principal focus de la infecci\u00f3 pneumoc\u00f2ccica. A m\u00e9s, s’ha estudiat la resist\u00e8ncia antibi\u00f2tica i la caracteritzaci\u00f3 gen\u00e8tica de les soques responsables de la malaltia mitjan\u00e7ant seq\u00fcenciaci\u00f3 completa del genoma. Els resultats obtinguts subratllen la capacitat del pneumococ per evolucionar i adaptar-se, la qual cosa posa de manifest la necessitat de mantenir una vigil\u00e0ncia constant i una actualitzaci\u00f3 de les estrat\u00e8gies de vacunaci\u00f3.<\/p>\n
Caracteritzaci\u00f3 gen\u00e8tica i emerg\u00e8ncia de nous serotips<\/strong><\/p>\nActualment s’han descrit m\u00e9s de 100 variants gen\u00e8tiques de S. pneumoniae<\/em>, conegudes com a serotips, que presenten difer\u00e8ncies quant a la capacitat d’ invasi\u00f3 i mortalitat associada. Al llarg dels anys, s’ha vist com la vacunaci\u00f3 ha provocat canvis en l’epidemiologia del pneumococ i els seus serotips, variant la pres\u00e8ncia d’aquests.<\/p>\nAra, aquest estudi ha identificat nous canvis, destacant la persist\u00e8ncia d’alguns serotips inclosos en la vacuna PCV13, com el serotip 3, i l’aparici\u00f3 de nous llinatges, com en el cas del serotip 4. A m\u00e9s, ressalta l’augment de serotips no inclosos en la vacuna PCV13, com el serotip 8. Aquests nous llinatges emergents estan contribuint a l’augment de l’MPI, assolint nivells que s’acosten als de l’\u00e8poca pre-pand\u00e8mica, i emfatitzant aix\u00ed la import\u00e0ncia de realitzar una caracteritzaci\u00f3 gen\u00e8tica per con\u00e8ixer les caracter\u00edstiques dels llinatges amb m\u00e9s capacitat de disseminaci\u00f3.<\/p>\n
L’impacte de la vacunaci\u00f3 infantil a l’MPI dels adults<\/strong><\/p>\nMalgrat els aven\u00e7os en la vacunaci\u00f3 infantil i l’impacte benefici\u00f3s que ha tingut per a la protecci\u00f3 en adults, la c\u00e0rrega de l’MPI en adults continua sent significativa. En particular, el serotip 3 continua sent un dels principals causants de malaltia greu en adults. Per aquesta ra\u00f3, caldria augmentar les taxes de vacunaci\u00f3 en adults, especialment despr\u00e9s de la introducci\u00f3 de les noves vacunes de major cobertura, primordialment en persones majors de 65 anys, immunodeprimits i aquelles amb comordilitats, per protegir directament els grups de poblaci\u00f3 m\u00e9s vulnerables.<\/p>\n
D’aquesta manera, l’estudi reafirma la import\u00e0ncia d’una vigil\u00e0ncia constant i l’actualitzaci\u00f3 de les vacunes contra el pneumococ, especialment per a la poblaci\u00f3 adulta. La caracteritzaci\u00f3 gen\u00e8tica dels serotips i el monitoratge de la resist\u00e8ncia antibi\u00f2tica s\u00f3n essencials per estar alerta davant l’evoluci\u00f3 adaptativa d’aquest important patogen.<\/p>\n
<\/p>\n
<\/p>\n
L’Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat el 2004. Est\u00e0 participat per l’ Hospital Universitari de Bellvitge i l’ Hospital de Viladecans de l’ Institut Catal\u00e0 de la Salut, l’ Institut Catal\u00e0 d’ Oncologia, la Universitat de Barcelona i l’ Ajuntament de l’ Hospitalet de Llobregat.<\/em><\/p>\nL’IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. El 2009 es va convertir en un dels cinc primers centres d’investigaci\u00f3 espanyols acreditats com a institut d’investigaci\u00f3 sanit\u00e0ria per l’Institut de Salut Carles III. A m\u00e9s, forma part del programa “HR Excellence in Research” de la Uni\u00f3 Europea i \u00e9s membre d’EATRIS i REGIC. Des de l’any 2018, IDIBELL \u00e9s un Centre Acreditat de la Fundaci\u00f3 Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n\u00a0<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"L’estudi subratlla la import\u00e0ncia d’incrementar la vacunaci\u00f3 en adults per prevenir la malaltia pneumoc\u00f2ccica invasiva, especialment en els grups de risc (adults grans i\/o amb comorbiditats).
\nEs constata la necessitat de continuar desenvolupant i millorant les vacunes contra pneumococs per ampliar la seva cobertura, atesa la gran capacitat d’adaptaci\u00f3 d’aquests pat\u00f2gens.<\/p>\n","protected":false},"author":8,"featured_media":26997,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[480,334,479],"tags":[],"class_list":["post-26996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-epidemiologia-de-les-infeccions-bacterianes-patogenesis-i-bases-moleculars-de-la-resistencia-al-antimicrobians","category-medicina-translacional","category-p-de-malalties-infeccioses-i-transplantaments"],"publishpress_future_action":{"enabled":false,"date":"2025-01-30 18:03:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26996"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26996\/revisions"}],"predecessor-version":[{"id":26998,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26996\/revisions\/26998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26997"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}